Compare · CBLL vs SMLR
CBLL vs SMLR
Side-by-side comparison of CeriBell Inc. (CBLL) and Semler Scientific Inc. (SMLR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and SMLR operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- CBLL carries a market cap of $1.03B.
- CBLL has hit the wire 7 times in the past 4 weeks while SMLR has been quiet.
- CBLL has more recent analyst coverage (8 ratings vs 6 for SMLR).
- Company
- CeriBell Inc.
- Semler Scientific Inc.
- Price
- -
- -
- Market cap
- $1.03B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- News (4w)
- 7
- 0
- Recent ratings
- 8
- 6
Semler Scientific Inc.
Semler Scientific, Inc. develops, manufactures, and markets proprietary products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Latest CBLL
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $131,754 worth of shares (4,887 units at $26.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by CeriBell Inc.
- CeriBell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ceribell Reports Third Quarter 2026 Financial Results
- Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
- Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $119,145 worth of shares (4,887 units at $24.38) as part of a pre-agreed trading plan (SEC Form 4)
- Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
- President and CEO Chao Xingjuan sold $521,775 worth of shares (20,846 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 746,345 units (SEC Form 4)
Latest SMLR
- SEC Form SCHEDULE 13G filed by Semler Scientific Inc.
- SEC Form 15-12G filed by Semler Scientific Inc.
- SEC Form EFFECT filed by Semler Scientific Inc.
- SEC Form EFFECT filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.
- SEC Form S-8 POS filed by Semler Scientific Inc.